Lantheus (LNTH) Competitors

$100.06 -2.94 (-2.85%)

As of 05/26/2026 04:00 PM Eastern

LNTH vs. INSM, BNTX, ROIV, MRNA, and VTRS

Should you buy Lantheus stock or one of its competitors? MarketBeat compares Lantheus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantheus include Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Lantheus compare to Insmed?

Insmed (NASDAQ:INSM) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.91	-$1.28B	-$5.75	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.11

Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

In the previous week, Insmed had 12 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Insmed and 4 mentions for Lantheus. Insmed's average media sentiment score of 1.13 beat Lantheus' score of 0.28 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus target price of $210.95, indicating a potential upside of 93.77%. Lantheus has a consensus target price of $99.71, indicating a potential downside of 0.35%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.1% of Lantheus shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Lantheus	18.05%	29.32%	15.00%

Summary

Insmed beats Lantheus on 9 of the 17 factors compared between the two stocks.

How does Lantheus compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

BioNTech has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Lantheus	18.05%	29.32%	15.00%

Lantheus has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.19	-$1.29B	-$5.88	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.11

BioNTech currently has a consensus price target of $128.44, indicating a potential upside of 39.23%. Lantheus has a consensus price target of $99.71, indicating a potential downside of 0.35%. Given BioNTech's higher possible upside, research analysts clearly believe BioNTech is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, BioNTech had 3 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for BioNTech and 4 mentions for Lantheus. BioNTech's average media sentiment score of 0.79 beat Lantheus' score of 0.28 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Lantheus on 9 of the 17 factors compared between the two stocks.

How does Lantheus compare to Roivant Sciences?

Lantheus (NASDAQ:LNTH) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Lantheus has a net margin of 18.05% compared to Roivant Sciences' net margin of -3,629.19%. Lantheus' return on equity of 29.32% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Roivant Sciences had 22 more articles in the media than Lantheus. MarketBeat recorded 26 mentions for Roivant Sciences and 4 mentions for Lantheus. Roivant Sciences' average media sentiment score of 0.43 beat Lantheus' score of 0.28 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.11
Roivant Sciences	$8.26M	2,570.80	-$299.77M	-$0.60	N/A

Lantheus currently has a consensus target price of $99.71, suggesting a potential downside of 0.35%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 13.22%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Lantheus and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Lantheus compare to Moderna?

Lantheus (NASDAQ:LNTH) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Lantheus presently has a consensus price target of $99.71, suggesting a potential downside of 0.35%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 24.02%. Given Lantheus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lantheus is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

In the previous week, Moderna had 9 more articles in the media than Lantheus. MarketBeat recorded 13 mentions for Moderna and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.28 beat Moderna's score of -0.11 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.11
Moderna	$1.94B	9.60	-$2.82B	-$8.15	N/A

Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Lantheus beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.32	-$3.51B	-$0.26	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.11

In the previous week, Lantheus had 1 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Viatris. Lantheus' average media sentiment score of 0.28 beat Viatris' score of -0.02 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Lantheus	18.05%	29.32%	15.00%

Viatris presently has a consensus target price of $16.43, suggesting a potential upside of 1.04%. Lantheus has a consensus target price of $99.71, suggesting a potential downside of 0.35%. Given Viatris' higher possible upside, research analysts clearly believe Viatris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Lantheus beats Viatris on 13 of the 16 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.71B	$8.52B	$6.46B	$12.34B
Dividend Yield	N/A	2.50%	2.76%	5.28%
P/E Ratio	24.11	16.32	21.07	25.81
Price / Sales	4.23	7.57	555.74	86.41
Price / Cash	16.13	17.11	43.49	56.67
Price / Book	5.37	4.05	10.36	7.17
Net Income	$233.56M	$224.05M	$3.56B	$336.99M
7 Day Performance	4.13%	4.45%	2.34%	2.87%
1 Month Performance	18.96%	1.31%	2.03%	3.16%
1 Year Performance	32.07%	0.83%	35.50%	35.93%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	2.0672 of 5 stars	$100.06 -2.9%	$99.71 -0.3%	+35.5%	$6.71B	$1.54B	24.11	1,193
INSM Insmed	3.5471 of 5 stars	$107.15 -1.8%	$210.95 +96.9%	+61.2%	$23.66B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.8118 of 5 stars	$88.85 -0.8%	$130.60 +47.0%	-6.5%	$22.65B	$3.25B	N/A	7,807
ROIV Roivant Sciences	2.5315 of 5 stars	$28.55 -2.5%	$30.55 +7.0%	+173.0%	$20.96B	$29.05M	N/A	860	Earnings Report Analyst Forecast High Trading Volume
MRNA Moderna	1.2924 of 5 stars	$48.11 -1.9%	$35.73 -25.7%	+79.1%	$19.46B	$1.94B	N/A	4,700	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors